|
Re: more on how ER+her2+ breast cancer differs from ER-her2+ bc
Hi Lani.
It is hard to know, considering all the variables. I still wonder whether I got as much cancer recurrence reduction out of receiving a doubled dose all the way through the final 4 out of 6 CAF treatments as one would get from the CAF itself. I wonder if that might actually be a significant variable among cancer patients that is being missed -- those who receive doubled doses vs those who don't, and the incidence of recurrence.
And if many breast cancers have steroid receptors which can actually be activated by the steroids given with the chemo, then that could help to explain why chemo works for some, but not all.
Thanks,
A.A.
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|
Hybrid Mode
